Pipeline

Our current pipeline reflects our focus on fighting the opioid crisis in the U.S.

Learn more about the results of CAM2038’s clinical trials:

Watch the video above for a description of FluidCrystal® Injection Depot Technology.

*FluidCrystal® trademark is owned by Camurus and used by Braeburn under license.